Retinal ALKBH5 inhibition induces myopia protection through selective regulation of ERK1/2 signaling
Peripheral blood m6A reduction correlates with human myopia severity. Retinal ALKBH5 upregulation drives myopia progression through ERK1/2 hyperactivation. Both pharmacological inhibition and genetic deletion of ALKBH5 effectively protect against myopia, attenuate inflammatory responses, and mitigate ECM dysregulation, mechanistically linked to the suppression of ERK1/2 signaling. These findings collectively identify ALKBH5 as a novel therapeutic target and DDO-2728 as a promising strategy for myopia control.
Authors
- Xin Yu (ORCID: https://orcid.org/0000-0002-8173-1555)
- Jianping Tong (ORCID: https://orcid.org/0000-0002-1562-6749)
- Xuhong Zhang (ORCID: https://orcid.org/0000-0002-8864-5326)
- Liyue Zhang (ORCID: https://orcid.org/0000-0001-6679-4411)
- Yanqing Li (ORCID: https://orcid.org/0000-0001-7030-5537)
- Ziyu Wang (ORCID: https://orcid.org/0000-0001-6138-6566)
- Jiayun Ge
- Ye Shen (ORCID: https://orcid.org/0000-0002-4891-8801)
- Xiang Li (ORCID: https://orcid.org/0000-0003-1950-0008)
- Zhitong Chen (ORCID: https://orcid.org/0000-0002-9142-281X)
- Yingying Wen (ORCID: https://orcid.org/0000-0003-4521-2253)
- Le Jin (ORCID: https://orcid.org/0009-0000-9622-1526)
- Jiru Zhu
- Yutong Xia
Institutions
- First Affiliated Hospital Zhejiang University (CN)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2025-11-12
- DOI
- https://doi.org/10.1186/s12967-025-07332-2
- Citations
- 1
- Primary Topic
- RNA modifications and cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.81